Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y1SI
|
|||
| Drug Name |
PMID25666693-Compound-100
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Patented | [1] | |
| Inflammatory pain [ICD-11: MG30.42; ICD-10: R52, G89] | Patented | [1] | ||
| Neuropathic pain [ICD-11: 8E43.0] | Patented | [1] | ||
| Osteoarthritis pain [ICD-11: MG30.31] | Patented | [1] | ||
| Company |
PURDUE PHARMA LP [USSHIONOGI & CO [JPTAFESSE LAYKEA [USANDO SHIGERU [JPKUROSE NORIYUKI [JP]
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H21F2N5O3S
|
|||
| Canonical SMILES |
CC1CN(CCN1C(=O)NC2=NC3=C(S2)C=CC(=C3)F)C4=C(C=C(C=N4)C(CO)O)F
|
|||
| InChI |
1S/C20H21F2N5O3S/c1-11-9-26(18-14(22)6-12(8-23-18)16(29)10-28)4-5-27(11)20(30)25-19-24-15-7-13(21)2-3-17(15)31-19/h2-3,6-8,11,16,28-29H,4-5,9-10H2,1H3,(H,24,25,30)/t11-,16+/m0/s1
|
|||
| InChIKey |
GVENNMJXQHKHOV-MEDUHNTESA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Transient receptor potential cation channel V1 (TRPV1) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
| Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.